Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Skinvisible (SKVI) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Skinvisible (SKVI) over the last 17 years, with Q3 2025 value amounting to 2121.14%.

  • Skinvisible's EBITDA Margin rose 3782400.0% to 2121.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 2904.44%, marking a year-over-year decrease of 2675300.0%. This contributed to the annual value of 2947.94% for FY2024, which is 4960700.0% down from last year.
  • As of Q3 2025, Skinvisible's EBITDA Margin stood at 2121.14%, which was up 3782400.0% from 2724.74% recorded in Q2 2025.
  • Skinvisible's EBITDA Margin's 5-year high stood at 58.35% during Q4 2021, with a 5-year trough of 3974.86% in Q4 2024.
  • Moreover, its 5-year median value for EBITDA Margin was 2262.2% (2023), whereas its average is 1782.5%.
  • As far as peak fluctuations go, Skinvisible's EBITDA Margin surged by 28287600bps in 2021, and later tumbled by -24254700bps in 2023.
  • Skinvisible's EBITDA Margin (Quarter) stood at 58.35% in 2021, then plummeted by -4135bps to 2354.32% in 2022, then decreased by -16bps to 2730.76% in 2023, then tumbled by -46bps to 3974.86% in 2024, then soared by 47bps to 2121.14% in 2025.
  • Its EBITDA Margin stands at 2121.14% for Q3 2025, versus 2724.74% for Q2 2025 and 2797.04% for Q1 2025.